These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 33800202)

  • 21. Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies.
    Randrian V; Evrard C; Tougeron D
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34205397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
    Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Evolving Landscape of Immunotherapy in Locally Advanced Rectal Cancer Patients.
    Germani MM; Carullo M; Boccaccino A; Conca V; Masi G
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor-agnostic drug development in dMMR/MSI-H solid tumors.
    Bhamidipati D; Subbiah V
    Trends Cancer; 2023 Oct; 9(10):828-839. PubMed ID: 37517955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Controversies and management of deficient mismatch repair gastrointestinal cancers in the neoadjuvant setting.
    Boutin M; Gill S
    Ther Adv Med Oncol; 2023; 15():17588359231162577. PubMed ID: 37007634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer.
    Akin Telli T; Bregni G; Vanhooren M; Saude Conde R; Hendlisz A; Sclafani F
    Cancer Treat Rev; 2022 Nov; 110():102460. PubMed ID: 36058142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape.
    Mulet-Margalef N; Linares J; Badia-Ramentol J; Jimeno M; Sanz Monte C; Manzano Mozo JL; Calon A
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831367
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors.
    Svrcek M; Lascols O; Cohen R; Collura A; Jonchère V; Fléjou JF; Buhard O; Duval A
    Bull Cancer; 2019 Feb; 106(2):119-128. PubMed ID: 30713006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair.
    Alex AK; Siqueira S; Coudry R; Santos J; Alves M; Hoff PM; Riechelmann RP
    Clin Colorectal Cancer; 2017 Sep; 16(3):228-239. PubMed ID: 28063788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer.
    Bui QL; Mas L; Hollebecque A; Tougeron D; de la Fouchardière C; Pudlarz T; Alouani E; Guimbaud R; Taieb J; André T; Colle R; Cohen R
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053568
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unraveling Resistance to Immunotherapy in MSI-High Colorectal Cancer.
    Heregger R; Huemer F; Steiner M; Gonzalez-Martinez A; Greil R; Weiss L
    Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors.
    Fucà G; Corti F; Ambrosini M; Intini R; Salati M; Fenocchio E; Manca P; Manai C; Daniel F; Raimondi A; Morano F; Corallo S; Prisciandaro M; Spallanzani A; Quarà V; Belli C; Vaiani M; Curigliano G; Cremolini C; De Braud F; Di Bartolomeo M; Zagonel V; Lonardi S; Pietrantonio F
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33849927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in immune therapies for the treatment of microsatellite instability‑high/deficient mismatch repair metastatic colorectal cancer (Review).
    Choucair K; Radford M; Bansal A; Park R; Saeed A
    Int J Oncol; 2021 Sep; 59(3):. PubMed ID: 34396449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
    Antoniotti C; Borelli B; Rossini D; Pietrantonio F; Morano F; Salvatore L; Lonardi S; Marmorino F; Tamberi S; Corallo S; Tortora G; Bergamo F; Brunella DS; Boccaccino A; Grassi E; Racca P; Tamburini E; Aprile G; Moretto R; Boni L; Falcone A; Cremolini C
    BMC Cancer; 2020 Jul; 20(1):683. PubMed ID: 32698790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge.
    Marmorino F; Boccaccino A; Germani MM; Falcone A; Cremolini C
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32824490
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy in Metastatic Colorectal Cancer: Could the Latest Developments Hold the Key to Improving Patient Survival?
    Damilakis E; Mavroudis D; Sfakianaki M; Souglakos J
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32268531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Case report: Efficacy of immunotherapy as conversion therapy in dMMR/MSI-H colorectal cancer: a case series and review of the literature.
    San-Román-Gil M; Martínez-Delfrade I; Albarrán-Fernández V; Guerrero-Serrano P; Pozas-Pérez J; Chamorro-Pérez J; Rosero-Rodríguez D; Sotoca-Rubio P; Barrill-Corpa AM; Alia-Navarro V; González-Merino C; García-de-Quevedo-Suero C; López V; Ruz-Caracuel I; Perna-Monroy C; Ferreiro-Monteagudo R
    Front Immunol; 2024; 15():1352262. PubMed ID: 38361927
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].
    Cohen R; Pudlarz T; Garcia-Larnicol ML; Vernerey D; Dray X; Clavel L; Jary M; Piessen G; Zaanan A; Aparicio T; Louvet C; Tournigand C; Chibaudel B; Tougeron D; Guimbaud R; Benouna J; Adenis A; Sokol H; Borg C; Duval A; Svrcek M; André T
    Bull Cancer; 2020 Apr; 107(4):438-446. PubMed ID: 32057467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The current value of determining the mismatch repair status of colorectal cancer: A rationale for routine testing.
    Ryan E; Sheahan K; Creavin B; Mohan HM; Winter DC
    Crit Rev Oncol Hematol; 2017 Aug; 116():38-57. PubMed ID: 28693799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.